Scholar Rock Holding Corporation (NASDAQ: SRRK) today announced new preclinical data from its TGFβ1 cancer immunotherapy program. In syngeneic mouse ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE